Erasca to Host Conference Call and Webcast to Discuss Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015
Rhea-AI Summary
Erasca (Nasdaq: ERAS) will host a conference call and live webcast on April 27, 2026 at 4:30 PM ET to discuss preliminary Phase 1 dose-escalation data for its pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors.
Investors can join via webcast at Erasca.com/events or by phone (1-877-407-3982 U.S./Canada; 1-201-493-6780 international).
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – ERAS
On the day this news was published, ERAS declined 10.89%, reflecting a significant negative market reaction. Argus tracked a peak move of +10.2% during that session. Argus tracked a trough of -61.2% from its starting point during tracking. Our momentum scanner triggered 97 alerts that day, indicating high trading interest and price volatility. This price movement removed approximately $816M from the company's valuation, bringing the market cap to $6.68B at that time. Trading volume was elevated at 2.5x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Pre-news, ERAS was down 4.36% while close biotech peers showed mixed moves (e.g., ALMS down, OLMA and PRTA up), and momentum peers REPL and ALMS moved in opposite directions, pointing to stock-specific factors rather than a broad sector move.
Previous Conferences,clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Sep 25 | Conference data preview | Positive | +8.1% | Announcement of preliminary SEACRAFT-1 Phase 1 data and investor R&D update. |
For similar conference/clinical data preview events, ERAS previously saw a positive price reaction.
This announcement continues Erasca’s pattern of highlighting early-stage clinical data and investor-focused events. A prior conferences,clinical trial update on Sep 25, 2024 about preliminary SEACRAFT-1 Phase 1 data and a virtual R&D update coincided with a +8.09% move. Recent filings describe encouraging early Phase 1 activity for ERAS-0015, expanded global rights, and multiple 2026–2027 readouts, underscoring a sustained emphasis on RAS-pathway programs and data communication.
Historical Comparison
Past conference/clinical data previews for ERAS, such as the 2024 SEACRAFT-1 update, saw an average move of 8.09%, framing expectations for how similar ERAS-0015 data events might be received.
Historical same-tag news highlighted preliminary naporafenib combination data and an investor R&D update; the current ERAS-0015 Phase 1 dose-escalation call reflects continued RAS-pathway development and data-sharing across the pipeline.
Regulatory & Risk Context
Erasca has an effective S-3 shelf filed on 2025-08-12 allowing issuance of up to $500,000,000 in securities, including a sale-agreement prospectus for up to $200,000,000 of common stock via an at-the-market program with Jefferies LLC. The company has used the shelf at least 2 times via recent 424B5 prospectuses, indicating established capacity to raise additional capital.
Market Pulse Summary
The stock dropped -10.9% in the session following this news. A negative reaction despite a data-focused conference call announcement would fit periods where investors reassessed risk around early-stage oncology programs and potential future financing. Prior filings highlighted narrowed 2025 net loss of $124.5M and a substantial $500,000,000 shelf with a $200,000,000 ATM component, so concerns could have centered on dilution or trial uncertainty rather than the logistics of the call itself.
Key Terms
phase 1 medical
dose escalation medical
molecular glue medical
ras/mapk pathway medical
pan-ras medical
AI-generated analysis. Not financial advice.
Conference call and live webcast today at 4:30 PM Eastern Time
SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss preliminary Phase 1 dose escalation data for its potentially best-in-class pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors today, Monday, April 27, 2026, at 4:30 pm ET.
Conference Call and Webcast Information
Erasca will hold a conference call and webcast Monday, April 27, 2026, at 4:30 pm ET. The webcast link for the conference call is here. The dial-in number is 1-877-407-3982 (U.S./Canada) or 1-201-493-6780 (international) or click the Call me™ Link. The live webcast and replay may be accessed by visiting Erasca’s website at Erasca.com/events.
About ERAS-0015
ERAS-0015 is an investigational, oral, highly potent pan-RAS molecular glue designed to inhibit RAS signaling with a potential best-in-class profile. Erasca is evaluating ERAS-0015 in the AURORAS-1 Phase 1 trial in patients with RAS-mutant solid tumors. Early dose escalation data in AURORAS-1 demonstrated favorable safety and tolerability results, well-behaved, linear PK, and confirmed and unconfirmed partial responses in multiple patients across multiple tumor types with different RAS mutations, including confirmed and unconfirmed partial responses at doses as low as 8 mg once daily (QD). ERAS-0015 is also designed to prevent resistance against mutant-selective inhibitors through inhibition of RAS wildtype variants. In addition, ERAS-0015 has demonstrated favorable absorption, distribution, metabolism, and excretion (ADME) and pharmacokinetic (PK) properties in multiple animal species.
About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
Source: Erasca, Inc.
